UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
February 9, 2007
---------------------------
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
-----------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
------------ ------------- --------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
---------------------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
---------------------
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On February 9, 2007, the Registrant and Dr. Behl entered into an
Amended and Restated Employment Agreement under which Dr. Behl's position was
changed from Chief Scientific Officer to Head of Technical Affairs and who is to
report to the Chief Executive Officer, the Chief Scientific Officer and any
additional executive officer designated by the Board of Directors of the
Registrant (the "Board"). In addition, the definition of "cause" has been
amended to include a determination by the Board, in its sole discretion, that
the employment of Dr. Behl should terminate, provided that such termination will
be effective on the 30th day after the written notice to Dr. Behl of such
determination.
ITEM 8.01 OTHER EVENTS
On February 14, 2007, the Registrant issued a press release announcing
the appointment of Veerappan Subramanian as its acting Chief Scientific Officer.
A copy of the press release is attached hereto as exhibit 99.1.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
a) Not applicable.
b) Not applicable.
c) Exhibits
10.1 Amended and Restated Employment Agreement, dated February 9,
2007, between the Registrant and Charan Behl, Ph.D.
99.1. Press Release, dated February 14, 2007
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: February 14, 2007
ELITE PHARMACEUTICALS, INC.
By: /S/ Bernard Berk
-------------------------------------
Name: Bernard Berk
Title: Chief Executive Officer
2